

Cover Story
PodcastThe Directors
By Sara Willa Ernst and Paul Goldberg
Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).
Podcast
Cancer Policy


In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Cancer hospitals brace for impact, as CMS moves to slash 340B payments by 33%
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Susan Wojcicki Foundation pushes for rethinking of strategies for early lung cancer detection
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Hegseth offers soldiers testosterone and FDA loosens safety warnings. Is the science there?




















